Revumenib is a prescription medicine indicated for the treatment of adult and pediatric patients aged 1 year and older with the following conditions:
1. Acute leukemia with lysine methyltransferase 2A (KMT2A) gene rearrangement, whose disease has relapsed or failed to improve following prior therapy;
2. Acute myeloid leukemia (AML) with nucleophosmin 1 (NPM1) gene mutation, whose disease has relapsed or failed to improve following prior therapy, and who have no other satisfactory treatment options.
FDA,2025.10
Your doctor may prescribe Revuforj tablets in multiple dosage strengths, and it ···【more】
Release date:2026-01-28Recommended:12
Revumenib is a menin inhibitor that blocks the interaction between wild-type lys···【more】
Release date:2026-01-28Recommended:13